<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497093</url>
  </required_header>
  <id_info>
    <org_study_id>CC-4047-MM-005</org_study_id>
    <nct_id>NCT01497093</nct_id>
  </id_info>
  <brief_title>Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Multiple Myeloma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in&#xD;
      combination with bortezomib and low-dose dexamethasone in subjects with relapsed or&#xD;
      refractory multiple myeloma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 3 + 3 design will be utilized to determine the MTD for POM + IV BTZ + LD-DEX combination&#xD;
      treatment in a 21-day treatment cycle. DLT will be assessed to determine MTD during the first&#xD;
      treatment cycle. Once the MTD is determined or the maximum planned dose (MPD) is reached&#xD;
      without reaching MTD for POM + IV BTZ + LD-DEX, a cohort of 6 additional subjects will be&#xD;
      treated at this MTD/MPD level to further confirm the safety and assess preliminary efficacy.&#xD;
      An additional cohort of subjects will be enrolled to explore the safety for the combination&#xD;
      of POM + BTZ + LD-DEX when using SQ BTZ. Subject in this cohort will receive POM + BTZ +&#xD;
      LD-DEX at the MTD/MPD level per the MTD determination part of the study, except, the BTZ will&#xD;
      be administered subcutaneously (SQ) instead of intravenously (IV). In, Protocol Amendment #4,&#xD;
      the number of subject enrolled to be enrolled into the exploratory SQ BTZ cohort was&#xD;
      increased from 6 to 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2012</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Number of participants with adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Number of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Overall response rate based on the International Myeloma Working Group (IMWG) Uniform response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Time from the initial documented response to confirmed disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Time from enrollment to the first documented response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide/Bortezomib/Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [&gt; 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle</description>
    <arm_group_label>Pomalidomide/Bortezomib/Dexamethasone</arm_group_label>
    <other_name>CC-4047</other_name>
    <other_name>Oral Pomalidomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression</description>
    <arm_group_label>Pomalidomide/Bortezomib/Dexamethasone</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [&gt; 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression</description>
    <arm_group_label>Pomalidomide/Bortezomib/Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Must be ≥ 18 years at the time of signing the informed consent form.&#xD;
&#xD;
          2. Subjects must have documented diagnosis of multiple myeloma and have measurable&#xD;
             disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).&#xD;
&#xD;
          3. Subjects must have had at least 1 but no greater than 4 prior anti-myeloma therapies.&#xD;
&#xD;
          4. Subjects must have received at least 2 consecutive cycles of prior treatment with&#xD;
             lenalidomide and must be refractory to their last lenalidomide-containing regimen&#xD;
             (either as a single agent or in combination).&#xD;
&#xD;
          5. Subjects must have received at least 2 consecutive cycles of prior treatment with a&#xD;
             proteasome inhibitor-containing regimen, but must not be refractory to bortezomib&#xD;
             (either as a single agent or in combination).&#xD;
&#xD;
          6. Subjects must have documented progression during or after their last anti-myeloma&#xD;
             therapy.&#xD;
&#xD;
          7. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             score of 0, 1, or 2.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subjects who are refractory to bortezomib either as single agent or in combination.&#xD;
&#xD;
          2. Subjects with peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
          3. Subjects with non-secretory multiple myeloma&#xD;
&#xD;
          4. Subjects with any of the following laboratory abnormalities:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,000/µL&#xD;
&#xD;
               -  Platelet count &lt; 75,000/µL for subjects in whom &lt; 50% of bone marrow nucleated&#xD;
                  cells are plasma cells; or a platelet count &lt; 30,000/ µL for subjects in whom ≥&#xD;
                  50% of bone marrow nucleated cells are plasma cells&#xD;
&#xD;
               -  Creatinine Clearance &lt; 45 mL/min according to Cockcroft-Gault formula&#xD;
&#xD;
               -  Corrected serum calcium &gt; 14 mg/dL (&gt; 3.5 mmol/L)&#xD;
&#xD;
               -  Hemoglobin &lt; 8 g/dL (&lt; 4.9 mmol/L; prior RBC transfusion or recombinant human&#xD;
                  erythropoietin use is permitted)&#xD;
&#xD;
               -  Serum glutamic oxaloacetic transaminase (SGOT)/ aspartate aminotransferase (AST)&#xD;
                  or Transaminase, serum glutamic pyruvic (SGPT)/ alanine aminotransferase (ALT) &gt;&#xD;
                  3.0 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          5. Subjects with prior history of malignancies, other than MM, unless the subject has&#xD;
             been free of the disease for ≥ 5 years. Except the following: Basal cell carcinoma of&#xD;
             the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix,&#xD;
             Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer (T1a&#xD;
             or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate&#xD;
             cancer that is curative.&#xD;
&#xD;
          6. Subjects with previous therapy with Pomalidomide&#xD;
&#xD;
          7. Subjects with hypersensitivity to thalidomide, lenalidomide, bortezomib, boron,&#xD;
             mannitol, or dexamethasone&#xD;
&#xD;
          8. Subjects with ≥ Grade 3 rash during prior thalidomide or lenalidomide therapy&#xD;
&#xD;
          9. Subjects who had any of the following within the last 14 days of initiation of study&#xD;
             treatment: Plasmapheresis, Major surgery (kyphoplasty is not considered major&#xD;
             surgery), Radiation therapy, Any anti-myeloma drug therapy&#xD;
&#xD;
         10. Subjects who have received any investigational agents within 28 days or 5 half-lives&#xD;
             (whichever is longer) of treatment&#xD;
&#xD;
         11. Pregnant or breastfeeding females&#xD;
&#xD;
         12. Men or women of childbearing potential or their sexual partners who are unwilling to&#xD;
             employ adequate contraception.&#xD;
&#xD;
         13. Subjects with known Human immunodeficiency virus (HIV) positivity or active infectious&#xD;
             hepatitis A, B, or C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amine Bensmaine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2. Erratum in: Leukemia. 2018 Oct;32(10):2305.</citation>
    <PMID>28642620</PMID>
  </reference>
  <reference>
    <citation>Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.</citation>
    <PMID>28967482</PMID>
  </reference>
  <reference>
    <citation>Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14.</citation>
    <PMID>28504846</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Relapsed and Refractory Multiple Myeloma</keyword>
  <keyword>Refractory Myeloma</keyword>
  <keyword>Resistant Multiple Myeloma</keyword>
  <keyword>Treatment-resistant Multiple Myeloma</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Lenalidomide-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

